Business Wire

CIRIUM

1.12.2021 01:02:14 CET | Business Wire | Press release

Share
Japan Domestic Flights Scheduled for Recovery in Q1 2022: Cirium Survey Reveals Sapporo and Okinawa as Top Destinations

The majority of Japanese travelers intend to take to the skies again, with 80% planning to travel in the next 12 months for leisure purposes (83%) and to domestic destinations, according to the new Cirium Traveler Intelligence Report.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211130006033/en/

Aviation analytics company Cirium records a noticeable increase in intention to travel across other markets surveyed, while travelers in Japan continue to be wary of the potential risks from COVID-19.

International travel is likely to remain difficult, however, there are encouraging indicators of recovery in Japanese domestic markets. Cirium data shows domestic traffic in Japan at 54% of 2019 levels, above the 49% average seen across APAC domestic markets excluding China.

Additionally, Cirium schedules data shows Japan is projected to reach 93% of 2019 Q1 traffic in the first quarter of 2022.

The recovery of international flights continues to be slow, but domestic traffic is recovering to pre-COVID levels experienced in 2019. According to the Cirium Japan survey, the prefectures of Sapporo and Okinawa are the most popular destinations for domestic travel, followed by Tokyo, Fukuoka and Osaka as secondary choices.

Jeremy Bowen, Cirium CEO, said: “The challenge is for airlines to make travelers feel safe about air travel and provide attractive and targeted offers to Japanese holiday makers to encourage travel.”

“At the same time, the tourism sectors needs to work collaboratively in making their region more appealing as a holiday destination and to entice Japan travelers to their prefectures.”

Further insights revealed several factors that could influence the intention to fly. One in five (20%) Japanese respondents will not book a flight until vaccines were fully deployed while almost half (42%) said a decrease in the number of COVID-19 cases will encourage travel.

Once international travel is permitted, nearly half (48%) of the respondents plan to take an international trip, with one-third selecting Europe as their choice of international destination.

The younger age group in Japan (18-29 year olds) expressed the most interest to fly again. Over two-thirds intended to fly within a year (68%) and over half (61%) plan to do so internationally with a preference for the region of East Asia.

When it comes to airline choice, Japanese carriers were clearly preferred with most citing All Nippon Airways as a favourite followed by Japan Airlines, Peach Aviation and Skymark Airlines.

Additional motivating reasons for choosing an airline over another are mandatory mask wearing on flight, requirement for health passports and improved cleaning processes on the aircraft.

The survey was carried out by independent market intelligence firm AudienceNet on behalf of Cirium. The firm interviewed over 2,092 adults in Japan between October 18 to 25, 2021. The margin of error in the reported data did not exceed +/-3% at the 95% confidence level.

Ends

Notes to editors

Click here to read the full Japan Cirium Traveler Intelligence Report.

Additional insights on air travel in the full report include:

  • The importance of flying on modern aircraft
  • Future use of airport lounges
  • Cabin class preferences
  • Top destinations in and outside of Japan

About Cirium

Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX , a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.

For further information please follow Cirium updates on linkedin or visit www.cirium.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release

Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye